Good morning, and welcome to the SWK Holdings Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note today’s event is being recorded. I would now like to turn the conference over to Jason Rando, Tiberend Strategic Advisors. Please go ahead.

Good morning, everyone, and thank you for joining SWK Holdings third quarter 2022 financial and corporate results call. Yesterday evening, SWK Holdings issued a press release detailing its financial results for the three months ended September 30, 2022. The Press release can be found in the Investor Relations section of swkhold.com under News Releases. Before beginning today's call, I would like to make the following statement regarding forward-looking statements. Today, we'll be making certain forward-looking statements about future expectations, plans, events and circumstances, including statements about our strategy, future operations and the development of our consumer and drug product candidates, plans for future potential product candidates and studies and our expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements. Actual results may differ materially due to our risks and uncertainties, including those detailed in the Risk Factors section of SWK Holdings 10-K filed with the SEC and other filings we make with the SEC from time to time. SWK Holdings disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise. Joining on today's call from SWK Holdings is Jody Staggs, President, Interim CEO; and Yvette Heinrichson, Chief Financial Officer. They will provide an update on SWK's third quarter and year-to-date corporate and financial results. Jody, go ahead.

Thanks, Jason, and thanks, everyone for joining our third quarter conference call. I'm excited to be speaking to you in my new role with SWK. This has been a productive past few months for the SWK team, and I look forward to sharing our progress. However, before doing so, I want to thank our Board for helping to ensure a successful leadership transition. And I also want to thank my predecessor, Winston Black, who has left SWK in a strong position. Winston is a longtime friend and [indiscernible] mentor. I'm grateful for this opportunity to build on the foundation he's left. I'd like to start with an overview of how I see the current business as well as a vision of where we are going. SWK's mission is to be the partner of choice for small to midsized life science companies seeking non-dilutive financing to fuel the development and commercialization of important lifesaving technologies. Since 2012, SWK has completed transactions with nearly 50 parties, funding almost $700 million. We think the results and the numbers produced over the past decade demonstrate that we are fishing in an attractive pond. Our focus is financing in the $5 billion to $25 million range, and we have created a niche and non-name-brand [ph] sponsored situations, a memory competitive field. We also focus on smaller off-the-road royalties, while most larger competitors gravitate towards Tier 1 high-profile royalties. We believe and think the numbers demonstrate that the returns in this segment are highly attractive. SWK targets a low to mid-teens return on our financings. During the third quarter, our effective yield was 14.3%, while our realized yield was 17.5%. We believe these returns are at the high end of our comp group. Our sweet spot has been and remains financings in the $7.5 million to…

Thank you, Jody. I appreciate the kind words, and I'm very happy to be here. I'd also like to thank you all for joining us this morning. SWK had a solid third quarter that was in line with expectations. As of September 30, 2022, SWK’s total investment assets grew by 8% to $222.2 million from $206.3 million for the third quarter of the previous year. Please note that, that quarter end figure does not include portfolio movement post quarter end. At the end of the quarter, the weighted average projected effective yield of our finance receivables portfolio, including non-accrual positions, was 14.3%. As Jody mentioned earlier, this is above SWK’s historical range and represent an increase from 13.8% from a year ago. Third quarter realized yield on finance receivables was 17.5% compared to 18.8% one year ago. SWK reported non-GAAP tangible financing book value per share at $19.14 as of September 30, 2022. That's a 9.4% increase from $17.50 as of September 30, 2021. This figure excludes the deferred tax assets, intangible assets, goodwill and contingent consideration payable. Management use tangible financing book value per share as a relevant metric to value the company's core finance receivables segment. The finance receivables segment's adjusted return on tangible book value was 11.1% as of September 30, 2022. For the third quarter 2022, SWK reported total revenues of $13.6 million. This is an increase from $9.6 million for the third quarter of 2021. The increase in revenue included recognition of $5 million of milestone revenue from Cara Therapeutics. Finance receivables segment revenue decreased to $8.5 million from $9.4 million from the previous year. The decrease in finance receivables segment revenue was primarily due to a $1.3 million net decrease in royalty income, which was primarily due to the achievement of return premium that caused a step down in royalty rates. That decrease in revenue was partially offset by a net increase of $0.4 million in interest and fees earned on our finance receivables. GAAP net income for the third quarter of 2022 totaled $6.6 million or $0.51 per diluted share, compared to $2.2 million or $0.17 per diluted share for the third quarter of 2021. The 2022 third quarter's net income reflected $1.1 million of severance payable to the former CEO. For the third quarter 2022, adjusted non-GAAP net income generated by our finance receivables segment was $6 million compared to $7.7 million for the third quarter of 2021. Back to you, Jody.

Thanks Yvette. In conclusion, SWK’s fundamentals are strong and the current market conditions are ideal for our custom financing solutions. We are working with our existing portfolio of companies to ensure they understand and are prepared for the challenging environment we face. We are urgently pursuing opportunities to scale the platform while thoughtfully deploying the capital. We are well positioned to capitalize on our reputation as a financing partner of choice for small and mid-sized life science companies. With that, I'll open the call for questions.

Thank you. We will now begin the question-and-answer session. [Operator Instructions] Today's first question comes from Kyle Bauser with Lake Street Capital Markets. Please go ahead.

Hey, guys. This is Jake on here for Kyle. Thanks for the updates and taking the question. I just have a couple of them for you guys today.

Thanks Jake.

So to get started, I was just wondering about the update on timing for adding leverage to the balance sheet. I know you talked about it being in the short-term, what is that looking into Q4, Q1 early?

Yes. Okay. If it was up to me, I list at my fingers and it would happen now. I think the first step, I expect us to have an update, very new term on math, so fourth quarter on the ABL. The second step, which we think could be the unsecured debt. I think it could happen relatively soon. There's a few challenges there. Number one is we do have to have our unsecured when there's approval to do a bond. And so that's a focus right now. And the second is the market conditions. It looks like today we're back in the bull market. So that's great. The 10 years down, and it's potentially opening up a window here. Six weeks ago, folks couldn't get farmed out. So, if the market is open and we can get kind of the paperwork lined up, it's something that I think we can get done in a reasonable period of time. I don't want to say an exact date and fourth quarter would be aggressive, but I think the watch word, I want to convey is there's a sense of urgency to get these things done.

Yes. Thanks for elaborating on that. And my next one talks about headcount. You mentioned you are currently at 6% and looking to be at 7%, I believe. Is there a potential need to keep adding more, or is the team all set in place?

Yes. So, we have an investor professional starting Monday and the -- that will bring our investment team to four, including me, and then our financial -- financing accounting team to three. I think we're at a decent baseline. We are looking and are considering bringing on sort of an experienced mid-level investment professional and then a business development person in 2023. If we can make those two hires -- and those aren't -- they are not things that need to happen tomorrow, I think that really puts the team in a great spot and gives us the kind of throughput unit to scale the platform. So, right now, I think we've got a decent baseline. We can add those two, I think we're going to be in great shape, and we just need to find the right people. We're really focused on every hire needs to be better than the people already here. And so we're being selective.

Yes, that's a good process for that, and that makes a lot of sense. And I just got one more for you guys today. So, what changes are you seeing in the level of deal activity out there compared to earlier this year? Thanks.

Yes. The -- there's been some fits and starts. Our portfolio is -- it's very healthy. If you had capital right now, I think we would have several deals that we would be pushing at close. I think what we're trying to do is really upgrade the situations we're looking at. So, the rates may be roughly the same as the things we've looked at, but we're looking to finance better assets, higher quality assets, more equity, better lender terms. There are numerous life science companies that are investment need capital and are reaching out and sort of presenting themselves to sort of second lien or kind of quasi equity situations. And then the returns on those, of course, is data returns look amazing, but we're really not focused there right now. So, pipeline is strong, lots of flow, and we're really just trying to sift through the things that kind of make sense for SWK.

Awesome. Thank you.

Okay. Thank you. Appreciate the question.

[Operator Instructions] Our next question comes from Scott Jensen of Private Investor. Please go ahead.

Good morning and congratulations, Jody, on your new position. And I too want to thank Winston for good stewardship of the capital over the years. I guess my first is thank you on the buyback and keep going. I'm glad that you still are. I think that's a good use of capital at these price levels. The second is you've answered most of them as far as capital and deal flow. So, thank you. As you talk about going into the asset management space, are there regulatory costs that come from that? And does that then determine the size that you need to make it a worthwhile venture?

Yes. Thanks for the question. Yes, just to echo Winston, the quarter -- these are -- as I said, there are seats that were planned quarters and years ago under his leadership. So, we're still benefiting from it. You had asset management concept is early. It's something that makes sense for us given what we do. The specific question around regulatory costs. We do have an OIA. So SWK, invests in OIA, so we have that already taken care of. I think a lot of it depends on what it is. Again, this is sort of me whiteboarding. This isn't necessarily a final plan. But if you go to sort of the GP LP fund, which would be the hardest to do, I think, particularly as we would be first-time fund boats. I think -- yeah, I think you're right the cost to do that would be higher the regulatory cost, we would need that IR outreach and of course, you've got to find those LPs that would require help. If you go all the way to the other side of a kind of like a fund of bond or maybe there's a general credit group that wants to allocate to cost space, I think the cost and the regulatory bond there is much lower. Now at the same time, you should expect the fees to scale from what's right as well. So does that answer the question?

Yes. Yeah, that helps. Thank you. And I guess my next one since most have been expanded upon already is obviously, you've shown great progress at Cara got another milestone, and you just presented your data for Ovarest in I think, last month. And I'm just kind of wondering what might be the next step there, both from a regulatory standpoint. This is a small Phase 2, but it was with an approved drug already. So that changes the need to prove that it's safe and effective. Are you thinking about partnering? Do you launch in on your own, which obviously that goes to a Phase 3 would be a higher cost structure. Are there any kind of thoughts about the next step for that drug?

Yeah. Let me make kind of a general statement and then maybe more specific statement. So given the leadership change and consider we've owned Enteris for three years, I feel like it made sense to just evaluate where we are and kind of where we're going with Enteris. So I'm working with the Enteris team and an adviser to really assess value, evaluate the assets and also the cost structure. And this is a process that just kicked off, and I don't have anything further than that. But we'll be able to tell you more, I think, in the fourth quarter. So just as a general comment, I think that's important to note. In terms of -- on Ovarest, I was actually speaking to the CMO a couple of days ago. And there is some interesting findings there in terms of full suppression of Estradiol in some of the samples. And Gary went out and did a paper on this. So it's out there. In terms of what exactly that means, we're going to understand more as we do this evaluation party and work with the team, the third-party. SWK's not funding the base story, just to be very clear.

Okay. Good.

It seems like they're interesting.

Yes.

Let me leave with the conclusion. SWK is not funding a Phase 3. So interesting asset, SWK is not in the drug development business, full stop. So hopefully, that answers your question.

Yeah. Yeah. Great. I mean just there's been so much interest in that space, the French government coming out and making it a priority to work on endometriosis. I mean there's just a lot of good interest. I would think somebody might have interest in the product. So thank you. That's great.

I think that could be right.

Okay. Great. I'll go back in line. Thanks and congratulations again.

Okay. Thank you, Scott.

[Operator Instructions] And ladies and gentlemen, this concludes the question-and-answer session. I'd like to turn the conference back over to Jody Staggs for closing remarks.

Thank you. And thanks, everyone, for joining the call. We appreciate your time and continued attention towards SWK. Please reach out to myself, Yvette or Tiberend with any follow-up questions. Have a great day.

Thank you, sir. This concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines, and have a wonderful day.